Literature DB >> 12186278

Varlirix (GlaxoSmithKline).

Ann M Arvin1.   

Abstract

GlaxoSmithKline (formerly SmithKline Beecham) has developed and launched Varilrix, a preparation of live, attenuated Oka-strain varicella zoster virus, for immunization against varicella zoster infections [455138]. By the end of 1998, Varilrix was available in a few European countries and in India [284490], [455138]. By 2001, the vaccine was also available in Brazil and Hong Kong [396267].

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12186278

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  3 in total

1.  Genetic profile of an Oka varicella vaccine virus variant isolated from an infant with zoster.

Authors:  Andreas Sauerbrei; Elena Rubtcova; Peter Wutzler; D Scott Schmid; Vladimir N Loparev
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

2.  Complete DNA sequences of two oka strain varicella-zoster virus genomes.

Authors:  Sueli L Tillieux; Wendy S Halsey; Elizabeth S Thomas; John J Voycik; Ganesh M Sathe; Ventzislav Vassilev
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

3.  Single-dose varicella vaccine effectiveness in school settings in China.

Authors:  Zhe Wang; Huili Yang; Keli Li; Aihua Zhang; Zijian Feng; Jane F Seward; Stephanie R Bialek; Chengbin Wang
Journal:  Vaccine       Date:  2013-07-08       Impact factor: 3.641
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.